# Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection

> **NCT02597166** · PHASE3 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 14 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Cirrhosis, Decompensated

## Interventions

- **DRUG:** Ledipasvir/Sofosbuvir

## Key facts

- **NCT ID:** NCT02597166
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2018-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597166, "Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02597166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*